Full-Time
Principal Software Test Lead
Updated on 8/21/2026
Haemonetics
1,001-5,000 employees
Provides plasma collection tech and services
Compensation Overview
$103.6k - $176.4k/yr
Boston, MA, USA
In Person
Bachelor's, Master's
 QA & Testing (1) |
|---|
Get referred to Haemonetics
See people who can refer or advise you
- The candidate must have 10 years of experience executing Verification and Validation strategy for Software as a Medical Device and Software as a Service platforms.
- The candidate must have a Bachelor's or Master's degree in Engineering, Computer Science, or a related field.
- The candidate must have strong expertise in test automation, quality metrics, and Agile methodologies.
- The candidate must have hands-on experience with traceability matrices and compliance frameworks.
- The candidate must have experience with Software as a Service and cloud-based systems.
- The candidate must have proven leadership experience mentoring and guiding engineering teams.
- The candidate must have strong analytical, problem-solving, and communication skills.
- Lead and define software Verification and Validation strategy for non-medical and medical-device software.
- Drive compliance with FDA design controls, IEC 62304, ISO 14971, and quality management systems.
- Provide technical leadership, mentorship, and review of Verification and Validation deliverables to ensure rigor, quality, and consistency across programs.
- Develop and implement robust test plans and test cases tailored to product and project needs.
- Oversee test design, execution, and Verification and Validation across application programming interfaces, user interfaces, backend systems, and integrated systems.
- Develop and implement automated testing strategies and promote a culture of automation.
- Establish, track, and report software quality metrics to drive data-informed decisions.
- Diagnose, document, and troubleshoot systems to resolve problems identified through testing and see them through to successful resolution.
- Recommend adjustments to resolve software issues and improve the functionality of existing software.
- Create and maintain traceability matrices linking requirements, risks, and verification and validation activities.
- Provide technical leadership and mentorship to engineers on Verification and Validation, compliance, and best practices.
- Collaborate cross-functionally with Development and Architecture teams, Quality Assurance, Product Owners, and business stakeholders to ensure comprehensive test coverage, conduct risk assessments, and drive defect resolution.
- Support audits, submissions, and inspections with complete, accurate, and traceable documentation.
- Drive continuous improvement in testing processes, efficiency, and integration within Agile workflows.
Haemonetics develops and sells medical technology solutions focused on improving plasma collection and critical-care operations in hospitals and plasma centers. Its products include devices and services that raise plasma yield, increase staff productivity, and enhance the donor experience, enabling healthcare providers to collect plasma more efficiently while maintaining patient care quality. The company generates revenue from one-time equipment sales and recurring service contracts and consumables used with its devices. It differentiates itself by targeting operational efficiency and patient outcomes in high-stakes settings, combining hardware, software, and services to streamline plasma collection and related processes. Haemonetics’ goal is to advance patient care by delivering reliable medical technologies that improve clinical performance and economic outcomes, while maintaining a strong focus on corporate responsibility.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Boston, Massachusetts
Founded
1971
Get referred to Haemonetics
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 6, 2026 guidance rose to 5%-8% reported revenue growth for fiscal 2027.
- Q1 fiscal 2027 revenue reached $339.4 million, up 5.6%, beating estimates.
- FDA clearance and label expansion on Persona PLUS and VASCADE MVP XL accelerate adoption.
What critics are saying
- Terumo BCT and Fresenius Kabi patent suits threaten plasma IP economics through 2027.
- Segment restructuring into Apheresis and MedSurg masks slowing Plasma and Blood Center comparability.
- Any Persona PLUS adoption stall exposes Haemonetics' growth engine and premium valuation by 2027.
What makes Haemonetics unique
- Persona PLUS and NexSys PCS deepen Haemonetics' plasma yield advantage in 2026.
- VASCADE MVP XL leads extravascular venous closure for electrophysiology and large-bore access.
- Martin Madaus joined the board July 24, 2026, strengthening healthcare operating oversight.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Company Match
Employee Stock Purchase Plan
Paid Vacation
Paid Sick Leave
Paid Holidays
Parental Leave
Disability Insurance
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
↑ 8%1 year growth
↑ 8%2 year growth
↑ 8%Haemonetics reported second-quarter results that beat Wall Street expectations, with revenue of $339.4 million versus analyst estimates of $330.2 million and adjusted earnings per share of $1.14 versus estimates of $1.08. The medical technology company's performance was driven by strong execution across its business lines, particularly in Plasma and Interventional Technologies. New product launches including Persona PLUS and VASCADE MVP XL drove adoption and utilisation. CEO Christopher Simon said all three core platforms contributed to the quarter's results, demonstrating the breadth of the business. Organic revenue rose 5.9% year on year, whilst operating margin remained steady at 16.9%. During the earnings call, analysts questioned management on topics including market share gains in Interventional Technologies, gross margin progression, Persona PLUS adoption timing, and capital equipment budgeting trends.
Haemonetics (HAE) projected to announce quarterly earnings on Thursday. July 30, 2026 Key points. * Haemonetics is expected to report Q1 fiscal 2027 results before the market opens on August 6, 2026. Analysts project earnings of $1.07 per share on $327.9 million in revenue, while full-year guidance is $5.258-$5.307 EPS. * In its latest quarter, Haemonetics earned $1.29 per share, exceeding estimates by $0.01, and generated $346.35 million in revenue - up 4.8% year over year and above consensus. * The stock recently rose 3.7% to $85.63, near its 52-week high, while analysts maintain a "Moderate Buy" consensus with an average price target of $78.89. Institutional investors own approximately 99.67% of shares. * Five stocks we like better than Haemonetics. Haemonetics (NYSE:HAE - Get Free Report) is projected to release its Q1 2027 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of $1.07 per share and revenue of $327.8930 million for the quarter. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Parties may visit the the company's upcoming Q1 2027 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET. Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, beating analysts' consensus estimates of $1.28 by $0.01. The firm had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. Haemonetics's quarterly revenue was up 4.8% on a year-over-year basis. During the same period last year, the firm posted $1.24 EPS. On average, analysts expect Haemonetics to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year. Haemonetics stock up 3.7%. Shares of Haemonetics stock opened at $85.63 on Thursday. Haemonetics has a one year low of $47.31 and a one year high of $87.32. The company has a market cap of $3.89 billion, a P/E ratio of 42.39, a PEG ratio of 1.66 and a beta of 0.52. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.87 and a current ratio of 2.95. The firm has a fifty day moving average of $74.25 and a two-hundred day moving average of $66.05. Analyst Ratings changes. Several research firms recently issued reports on HAE. Robert W. Baird set a $67.00 price target on shares of Haemonetics in a report on Friday, May 8th. Citigroup reaffirmed a "buy" rating on shares of Haemonetics in a report on Wednesday. Bank of America upgraded Haemonetics from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $72.00 to $80.00 in a research report on Friday, May 22nd. Weiss Ratings raised Haemonetics from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, June 25th. Finally, JPMorgan Chase & Co. reduced their price target on Haemonetics from $74.00 to $62.00 and set a "neutral" rating for the company in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Haemonetics currently has a consensus rating of "Moderate Buy" and an average price target of $78.89. Discover more Self-Help & Motivational Financial News Institutional trading of Haemonetics. A number of institutional investors have recently added to or reduced their stakes in the stock. Kemnay Advisory Services Inc. acquired a new position in Haemonetics during the fourth quarter worth about $26,000. EverSource Wealth Advisors LLC lifted its position in shares of Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier's stock valued at $31,000 after acquiring an additional 396 shares during the period. Kestra Advisory Services LLC acquired a new stake in shares of Haemonetics during the 4th quarter valued at approximately $34,000. UMB Bank n.a. boosted its stake in shares of Haemonetics by 110.9% during the 4th quarter. UMB Bank n.a. now owns 582 shares of the medical instruments supplier's stock worth $47,000 after acquiring an additional 306 shares in the last quarter. Finally, Parallel Advisors LLC boosted its stake in shares of Haemonetics by 172.9% during the 4th quarter. Parallel Advisors LLC now owns 625 shares of the medical instruments supplier's stock worth $50,000 after acquiring an additional 396 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock. About Haemonetics. Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management. The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Haemonetics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list. While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain - combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Haemonetics Corporation has appointed Martin Madaus to its board of directors, effective 24 July 2026. The Boston-based medical technology company focuses on delivering medical solutions for better patient outcomes. Madaus brings over 30 years of leadership experience in diagnostics and life sciences. He currently serves as senior operating executive at The Carlyle Group, where he has advised on healthcare investments since 2019. Previously, he led Ortho Clinical Diagnostics as chairman and CEO following its separation from Johnson & Johnson, and headed Millipore Corporation's transformation before its 2010 acquisition by Merck KGaA. He also chairs Repligen Corporation's board and serves on Azenta's board. Madaus holds veterinary medicine degrees from German universities.
MTD Micro Molding promotes John Clark to CEO. The longtime MTD leader returned to guide its next era of innovation and operational excellence in precision micro manufacturing. June 15, 2026 Associate Editor MTD Micro Molding revealed that it has named John Clark as its new CEO, effective June 10. Clark boasts over two decades of expertise in tooling, operations, and high-precision medical manufacturing. He also brings a deep, firsthand understanding of the steps needed to reliably produce increasingly complex miniaturized components, the company said. He first joined MTD in 2008 as a toolmaker and became a key leader, overseeing completion of the facility addition that doubled the company's manufacturing footprint. His return earlier this year began as director of operations before MTD appointed him as CEO. The company said that he returned because he believes "there's no team in the industry that does what MTD does." "Customers today are more informed about micro molding than ever," said Clark, "asking detailed questions about equipment, process discipline, and technical capabilities. What they're looking for is what MTD has been developing for decades. This isn't a new niche for us. We're the ones who defined - and continue to redefine - what this work requires." Clark's appointment comes less than a month after MTD announced former Haemonetics executive Chad Nikel would lead the company. In a statement to MPO, MTD said Nikel resigned to pursue another opportunity. The company said it recently optimized what might be the smallest overmold design in its 50-year history. In 2026's first five months, MTD produced four million components across 45 production molds, including tiny orthopedic implants with dead-sharp tips, thin-wall components for minimally invasive procedures, bioresorbable implants, and intricate multi-step overmolded devices. The company also reactivated internal lab and testing equipment to advance materials analysis capabilities, supporting more precise polymer characterization across complex programs. "By investing ahead of industry needs and developing capabilities before they're required," said Clark, "we help our customers bring the next generation of medical devices to market with confidence." "Dennis used to say that what made MTD special was the team's mentality - taking on the projects that start with some element of impossibility and finding a way to conquer them," said Darlene Tully, owner of MTD Micro Molding. "John has carried that mentality throughout his career here. He doesn't make promises he can't keep, and he builds teams and processes that deliver on the ones he does. That's the foundation of every customer relationship MTD has, and it's why I trust him to lead this company Ever Forward."
Haemonetics shares rose 3.4% after BofA Securities upgraded the blood products company to Buy from Neutral, raising its price target to $80 from $72. The analyst cited stronger performance in the vascular closure business and steady plasma demand as growth drivers. BofA noted that Haemonetics has set conservative guidance for the upcoming year, making outperformance likely. Whilst US plasma collections grew in the high single digits in the most recent fiscal quarter, the company's guidance incorporates only 0-2% growth. The upgrade follows Haemonetics' recent earnings report, where it surpassed analyst expectations for both revenue and earnings per share. The stock is down 19.9% year-to-date, trading 26.5% below its 52-week high of $87.16 from December 2025.